Brivekimig

N/A

Report date: 2026/05/25 20:02:40

Base Information

Drug NameBrivekimig
Drug Alias NameSAR-442970SAR442970
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)
Mechanisms of ActionTumor necrosis factor α inhibitorsAnti-Tumor necrosis factor receptor superfamily member 4
TargetsTumor necrosis factor αTumor necrosis factor receptor superfamily member 4
Therapy Area/IndicationsInflammationDiabetes Mellitus, Type 1Nephrosis +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[30] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesSanofiSanofi-Aventis Deutschland GmbhSanofi-Aventis Recherche & Developpement +[5] 
Inactive CompaniesN/A
Active IndicationsInflammationDiabetes Mellitus, Type 1Nephrosis +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A